Zymeworks Announces Participation in Upcoming Investor Conferences
February 28 2023 - 8:30AM
Business Wire
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology
company developing novel, multifunctional biotherapeutics, today
announced that management will participate in the following
upcoming investor conferences:
- Barclays Global Healthcare Conference. Zymeworks’ management
will participate in one-on-one meetings on March 14-15 and present
on March 14th at 10:45 am Eastern Standard Time (EST) in Miami
Beach, FL.
- Cantor: The Future of Oncology Virtual Symposium. Zymeworks’
management will participate virtually in one-on-one meetings on
April 3-4 and participate in a fireside chat.
All presentations and webcasts will be available on Zymeworks’
website at http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company
committed to the discovery, development, and commercialization of
novel, multifunctional biotherapeutics. Zymeworks' mission is to
make a meaningful difference for people impacted by
difficult-to-treat cancers and other serious diseases. Zymeworks'
complementary therapeutic platforms and fully integrated drug
development engine provide the flexibility and compatibility to
precisely engineer and develop highly differentiated antibody-based
therapeutic candidates. Zymeworks engineered and developed
zanidatamab, a HER2-targeted bispecific antibody using Zymeworks'
proprietary Azymetric™ technology. Zymeworks has entered into
separate agreements with BeiGene, Ltd. (BeiGene) and Jazz
Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene
and Jazz with exclusive rights to develop and commercialize
zanidatamab in different territories. Zanidatamab is currently
being evaluated in global Phase 1, Phase 2, and Phase 3 clinical
trials, including certain ongoing pivotal clinical trials as a
treatment for patients with HER2-expressing cancers. Zymeworks'
next clinical candidate, zanidatamab zovodotin (ZW49), is a
HER2-targeted bispecific antibody-drug conjugate (ADC) developed
using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin
technologies. Zanidatamab zovodotin is currently being evaluated in
a Phase 1 clinical trial for patients with a variety of
HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks
is also advancing a deep pipeline of product candidates based on
its experience and capabilities in both ADC and multispecific
antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline,
its therapeutic platforms have been further leveraged through
strategic partnerships with global biopharmaceutical companies. For
information about Zymeworks, visit www.zymeworks.com and follow
@ZymeworksInc on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230228005304/en/
Investor Inquiries: Jack Spinks Director, Investor Relations
(604) 678-1388 ir@zymeworks.com
Media Inquiries: Diana Papove Director, Corporate Communications
(604) 678-1388 media@zymeworks.com
Zymeworks (NASDAQ:ZYME)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zymeworks (NASDAQ:ZYME)
Historical Stock Chart
From Jul 2023 to Jul 2024